Our Pipeline

Pioneering the development of therapeutics to modulate DNA Damage Response

DNA Damage Response Modulators

Our pipeline of DNA Damage Response modulators includes novel inhibitors of ATR and WEE1.

 

ATRN-119: Novel macrocyclic ATR inhibitor

  • Unique biomarkers identified for optimized patient selection

  • Differentiated, macrocyclic molecular structure

  • Potential for lower hematological toxicity versus other ATR inhibitors

  • Phase 1 clinical trial commenced 1Q, 2023

 

ATRN-W1051: Novel WEE1 inhibitor

  • Promising anti-tumor activity in tumor model

  • Potential for improved PK properties versus other WEE1 inhibitors

  • Excellent selectivity for WEE1 versus PLK1/2/3, potentially limiting off-target toxicity

  • Nanomolar anti-proliferative activity against multiple cancer cell lines

  • IND filing anticipated 4Q, 2023

DDR PIPELINE

MOLECULE
TARGET
INDICATION
BIOMARKER
Preclinical
IND-Enabling
Phase 1
Anticipated Milestones
ATRN-119
ATRn-1051
ATRN-354 1
APRE-DDRi
ATR
WEE1
ATR
DDR Target
Advanced solid tumors
Ovarian, breast, prostate
Advanced solid tumors
Advanced solid tumors
Advanced solid tumors
Define biomarkers
BRAC1/2 + others
CCNE amplification + others
Defined biomarkers
Defined biomarkers
Q1 2024: Phase 1 tolerability, PK

Q4: 2023 / Q1 2024: Ph1 initiation
monotherapy
combination with PARPi
End of 2023: IND submission
Second half of 2024: IND submission
Mid-2024: Development candidate

DDR PIPELINE